conferenceseries.com

32nd International Conference on

Vaccines and Immunization

March 21-22, 2019

Rome, Italy



SCIENTIFIC PROGRAM

DAY 1
Thursday, 21st March

08:30-09:00 **Registrations**

09:00-09:30 **Introduction**

09:30-09:50 COFFEE BREAK

09:50-11:50 Meeting Hall 01 **KEYNOTE LECTURES**

11:50-13:10 **MEETING HALL 01**

Talks On:

Bacterial and Viral Vaccines	DNA, Protein and Toxoid Vaccines
Vaccines against infectious diseases	Combination and Conjugate Vaccines
Cancer Vaccines	Travel and edible Vaccines

13:10-13:15 GROUP PHOTO

13:15-14:00 LUNCH BREAK

14:00-16:00 **MEETING HALL 01**

Talks On:

- Paediatric Vaccination
- Vaccines for Immune mediated diseases
- Vaccine production and delivery technologies

16:00-16:20 COFFEE BREAK

MEETING HALL 01 (16:20-17:00)

Vaccine Production & Development

DAY 2
Friday 22nd March

09:00-10:30 Meeting Hall 01 — **KEYNOTE LECTURES**

10:30-10:50 COFFEE BREAK

10:50-12:50 — **MEETING HALL 01**

Talks On:

- Vaccine Safety and Efficacy
- Geriatric Immunization
- Animal Models and Clinical Trails
- Malaria and TB Vaccines

12:50-13:35 LUNCH BREAK

13:35-15:55 — **MEETING HALL 01**

Talks On:

- Vaccination for Emerging and Re-emerging diseases
- Vaccines Industry and Manufacturing
- Vaccines for unconventional diseases
- Vaccines for pregnant women and Neonates

15:55-16:15 COFFEE BREAK

MEETING HALL 01 (16:15-17:00)

Poster Presentations

Previous Organizing Committee



Eli Boritz

Chief, Virus Persistence and Dynamics Section (VPDS)
NIAID USA



Francisco Diaz Mitoma

Chair of The Board of Directors
Bowhead Health, University of Alberta
Canada



Ivana Haluskova Balter

Administrative Board Member
French society of immunology
France



Natalia Romanenkova

Pasteur Institute in
St. Petersburg
Russia"



Pramod Jog

President
Indian Academy of Pediatrics,
Standing Committee Member
of IPA, Steering Committee
Member of GAVI
India



Tong-Ming Fu

Senior Scientist
Merck and Company
USA

PAST AFFILIATES

PAST AFFILIATES

Pierre A MORGON
CEO MRGN Advisors, Switzerland

Poupak Fallahi
University of Pisa, Italy

Silvia Martina Ferrari
University of Pisa, Italy

Liliya Pekova
Trakia University, Bulgaria

Peter Timms
University of the Sunshine Coast, Australia

Yoshinori HAYAKAWA
Toin University of Yokohama, Japan

Md Jasim Uddin
International Centre for Diarrhoeal Disease Research, Bangladesh

Debaki R Howlader
National Institute of Cholera and Enteric Diseases, India

Pramod Jog
Dr. D. Y. Patil Medical College, India

Keshan Zhang
Lanzhou Veterinary Research Institute, China

J Santiago Mejia
Oxford Immunotec, USA

Yanelys Morera Diaz
Center for Genetic Engineering and Biotechnology, Cuba

Gabriel Kristian Pedersen
Statens Serum Institut, Denmark

Carmen Alvarez-Dominguez
Instituto de Investigación Marqués de Valdecilla, Spain

Mario A Bianchet
Johns Hopkins School of Medicine, USA

Marek Chmielewski
The Polish Academy of Sciences, Poland

Frederic J Deschamps
University Hospital of Reims, France

Randa S Hamadeh
Ministry of Public Health, Lebanon

Catherine Heffernan
Public Health England, UK

Pragya Sharma
Maulana Azad Medical College, India

Helen Bright
Medimmune, UK

Klara Stensvag
University of Tromsø - The Arctic University of Norway, Norway

Haihong Hao
Huazhong Agricultural University, China

Iskakova Zhanar Baktybaevna
Kazakh University of Technology and Business, Kazakhstan

Yuguang Mu
Nanyang Technological University, Singapore

PAST AFFILIATES

PAST AFFILIATES

Amin Noori
Social Security Hospital, Iran

Marek Malecki
Phoenix Biomolecular Engineering Foundation, USA

Roberto Grau
Universidad Nacional de Rosario, Argentina

Chit Laa Poh
Sunway University, Malaysia

Godwin W Nchinda
CIRCB, Cameroon

Xiao-Song He
VA Palo Alto Health Care System, USA

Mark Fife
The Pirbright Institute, UK

Rongtuan Lin
McGill University, Canada

Clayton A Dehn
High Point Clinical Trials, USA

Manja Marz
Friedrich Schiller University Jena, Germany

Francis O Eko
Morehouse School of Medicine, USA

Oreola Donini
Soligenix, Inc., USA

Bryan Knight
Southern IML Pathology, Australia

Yang Jiaying
Southeast University, China

Bin Lu
MedImmune, USA

Li Luo
Southeast University, China

Chien-Fu Hung
The Johns Hopkins University, USA

Claudia Leon-Sicairos
Autonomous University of Sinaloa, Mexico

Gurfateh Singh
Rayat Bahra University, India

Katarzyna Sitarz
Jagiellonian University Medical College, Poland

Stef Stienstra
Civil-Military-Interaction-Command Royal Dutch Armed Forces, Netherlands

Wenping Gong
The 309th Hospital of PLA, China

Cheng-Chuan Su
Tzu Chi University, Taiwan

Naveed Shahzad
University of the Punjab Lahore, Pakistan

Luo Yanping
General Hospital of Chinese PLA, China

Iqbal Sami
TB Hospital, Pakistan

PAST AFFILIATES

PAST AFFILIATES

Meth Akash
District General Hospital, Srilanka

Suliman Qadir Afridi
Technische Universität München, Germany

Naser Nazari
Kermanshah University of Medical Sciences, Iran

Zhang Youjiang
General Hospital of Chinese PLA, China

Wenya Huang
National Cheng Kung University, Taiwan

Shan Lu
University of Massachusetts Medical School, USA

Igor S Lukashevich
University of Louisville, USA

Kei Amemiya
US Army Medical Research Institute of Infectious Diseases, USA

Peter Johannes Holst
University of Copenhagen, Denmark

Magdalena Tary-Lehmann
Cellular Technology Limited, USA

Didier Clenet
Sanofi-Pasteur, France

Weiping Zhang
Kansas State University, USA

Randa Hamadeh
Ministry of Public Health, Lebanon

Klaus Schwamborn
Valneva SE, France

Cyrielle Fougeroux
Copenhagen University, Denmark

Zrinka Oreskovic
Veterinary Research Institute, Czech Republic

Touraj Aligholipour Farzani
Ankara University, Turkey

Pascal Breton
VitamFero, France

Ger T Rijkers
University College Roosevelt, Netherlands

Karola Rittner
Transgene SA, France

Mohammad Hossein Yazdi
Tehran University of Medical Sciences, Iran

Hsin-Wei Chen
National Health Research Institutes, Taiwan

Fumihiko Takeshita
Daiichi Sankyo Co. Ltd., Japan

Ming-Hsi Huang
National Health Research Institutes, Taiwan

Ana Gervassi
Center for Infectious Disease Research, USA

PAST AFFILIATES

PAST AFFILIATES

James D Cherry
University of California, USA

Sudhir Paul
University of Texas - Houston Medical School USA

Giulio Tarro
Foundation T. & L. de Beaumont Bonelli for cancer research, Italy

John Howard
Applied Biotechnology Institute, USA

Pei-Yong Shi
University of Texas Medical Branch, USA

Catherine H. Schein
University of Texas, USA

Robert L Hunter
University of Texas Health Sciences Center, USA

Brandon DeKosky
The University of Kansas, USA

Qizhi Cathy Yao
Baylor College of Medicine, USA

Jay Tischendorf
Merck Animal Health, USA

Charles E McKenna
University of Southern California, USA

Alexander Bukreyev
University of Texas, USA

Dan Bustillos
University of Washington Bothell, USA

Gesine Heuck
Precision NanoSystems Inc., Canada

Remya Mohanraj
Houston Community College, USA

Saifan Al Obaidi
Al-Nahrain University School of Medicine, Iraq

Aycan Gundogdu
Erciyes University School of Medicine, Turkey

Tatiana Massarrah
Gregorio Maranon Hospital, Spain

Sherry A Bradford
AccuTheranostics Inc, USA

Charles L Hitchcock
The Ohio State University, USA

Alice Dragomir
McGill University, Canada

Audrey Claing
Montreal University, Canada

Hirendra Banerjee
University of North Carolina, USA

Katarina Jeremić
Clinical Center of Serbia, Serbia

Italy Attractions



Vaccine Summit Reminisce













Glimpses of Vaccine Conferences

















conferenceseries.com
1571st Conference

Scientific Program

29th International Conference on

VACCINES AND IMMUNIZATION

March 19-20, 2018 | London, UK



UK: Conference Series llc LTD
47 Churchfield Road, London, W3 6AY
Toll Free: +0-800-014-8923

Day 1 March 19, 2018

08:30-09:30 Registrations

Bleriot 2

conferenceseries.com 09:30-10:00 **Opening Ceremony**

Keynote Forum

10:00-10:10 **Introduction**

10:10-10:50 **Title: Successfully activating positive behaviors of the stakeholders involved in vaccine purchasing and usage through technological advances**
Pierre A MORGON, MRGN Advisors, Switzerland

Group Photo

Networking and Refreshments Break 10:50 -11:10 @ Breakout Area

11:10-11:50 **Title: Vaccines and type 1diabetes**
Poupak Fallahi, University of Pisa, Italy

11:50-12:30 **Title: Viruses and type 1 diabetes**
Silvia Martina Ferrari, University of Pisa, Italy

Sessions: Human Vaccines against Infectious Diseases | Veterinary Vaccines | Paediatric Vaccination

Session Chair: Pierre A MORGON, MRGN Advisors, Switzerland

Session Introduction

12:30-12:55 **Title: Influenza associated neurological complications – clinical course and prognostic factors**
Liliya Pekova, Trakia University, Bulgaria

Lunch Break 12:55-13:55 @ RBG

Workshop

13:55-14:55 **Title: How to overcome resistance to vaccination recommendations!!!**
Pierre A MORGON, MRGN Advisors, Switzerland

General Session

14:55-15:20 **Title: Development of a chlamydial vaccine for koalas: Protection against infection as well as disease**
Peter Timms, University of the Sunshine Coast, Australia

15:20-15:45 **Title: Proposal of method creating artificial pandemic by infectious attenuated vaccine for reducing victims of new bird type influenza pandemic–operation backfire**
Yoshinori HAYAKAWA, Toin University of Yokohama, Japan

Networking and Refreshments Break 15:45-16:05 @ Breakout Area

16:05-16:30 **Title: Innovative approaches for improving child immunization coverage in urban slums of Bangladesh**
Md Jasim Uddin, International Centre for Diarrhoeal Disease Research, Bangladesh

16:30-16:55 **Title: Bivalent outer membrane vesicles based immunogen of *S. typhi* and Paratyphi A induce adaptive immunity and protective efficacy in mice**
Debaki R Howlader, National Institute of Cholera and Enteric Diseases, India

Panel Discussion

Day 2 March 20, 2018

Bleriot 2

Keynote Forum

10:00-10:10	**Introduction**
10:10-10:50	**Title: How do we prioritize vaccines for different countries?** **Pramod Jog,** Dr. D. Y. Patil Medical College, India
	Networking and Refreshments Break 10:50-11:10 @ Breakout Area
11:10-11:50	**Title: Proposal of artificial pandemic of infectious attenuated live influenza vaccine for saving the world from dangerous wild type new influenza pandemic–operation backfire** **Yoshinori HAYAKAWA,** Toin University of Yokohama, Japan

Sessions: Veterinary Vaccines | Current Research & Future Challenges | Cellular Immunology & Latest Innovations | Vaccine Safety & Efficacy | Antibodies: Engineering & Therapeutics | Cancer, Malaria & TB Vaccines

Session Chair: J Santiago Mejia, Oxford Immunotec, USA

Session Introduction

11:50-12:15	**Title: Maternal antibody has negative effect on foot and mouth disease vaccine immune in piglets** **Keshan Zhang,** Lanzhou Veterinary Research Institute, China
12:15-12:40	**Title: BluePort tissue platform: A tool to induce and study pan-arthropod immunity** **J Santiago Mejia,** Oxford Immunotec, USA
12:40-13:05	**Title: Immunology as applied to vaccination** **Pramod Jog,** Dr. D. Y. Patil Medical College, India

Lunch Break 13:05-14:05 @ RBG

14:05-14:30	**Title: A comparative study between Pyrogen and LAL tests for determination of endotoxin level in some biological products** **Mohammed Elkhateeb,** National Organization for Research and Control of Biologicals, Egypt
14:30-14:55	**Title: Site attachment inhibition therapeutics: Considerations regarding new generation immunization schedules** **Simon Raymond,** Melbourne University, Australia
14:55-15:20	**Title: Immune response in patients with advanced solid tumors after long-term immunization with a VEGF therapeutic vaccine** **Yanelys Morera Diaz,** Center for Genetic Engineering and Biotechnology, Cuba
15:20-15:45	**Title: The role of Auto ZelK BRIDGE software, hardware, and bioelectronics in biomedical and space science advanced research and new vaccine and drug discovery and development** **Zelalem Kiros Bitsue,** United States of African Health Organization, Ethiopia

Networking and Refreshments Break 15:45-16:05 @ Breakout Area

Panel Discussion

Poster Presentations 16:05-16:35 @ Foyer

VACS1	**Contraceptive potential of *E. coli* expressed recombinant protein encompassing sperm associated protein and GnRH** **Vidisha Minhas,** National Institute of Immunology, India
VACS2	**Linear doggybone™ DNA vaccine induces comparable immunological responses to conventional plasmid DNA vaccine via STING and independently of TLR9** **Chuan Wang,** University of Southampton, UK
VACS3	***In vivo* tracking of measles vaccine: Playing with new imaging tools** **Emmanuelle Billon-Denis,** Armed Forces Biomedical Research Institute, France

Awards & Closing Ceremony

conferenceseries.com
888th Conference

Scientific Program

15th Annual Summit on

Vaccines and Immunization

February 20-21, 2017 Berlin, Germany



UK: Conference Series llc LTD
47 Churchfield Road, London, W3 6AY, Tel: +1-800-216-6499
Email: vaccinessummit@conferenceseries.net, vaccinessummit@vaccineconference.com

Registrations

Sylt 1-2

conferenceseries.com

Opening Ceremony

Keynote Forum

Introduction

Title: The VCG platform facilitates mucosal and systemic vaccine delivery for induction of protective immunity in the female genital tract

Francis Eko, Morehouse School of Medicine, USA

Title: From human vaccines for viral diseases to those ones for oncogenic viruses and tumor antigens

Giulio Tarro, Foundation de Beaumont Bonelli for Cancer Research, Italy

Coffee Break

Sessions:

Vaccine Delivery Systems and Adjuvants | Vaccine Production and Delivery Technologies | Hepatitis, HIV and STD Vaccines | Vaccination for Emerging and Re-emerging Diseases | Cancer Vaccines

Session Chair: Giulio Tarro, Foundation de Beaumont Bonelli for Cancer Research, Italy
Session Co-chair: Yusuf Omosun, Morehouse School of Medicine, USA

Session Introduction

Title: VCG modulate innate and adaptive immunity to vaccine antigens
Yusuf Omosun, Morehouse School of Medicine, USA
Title: The emerging role of ASC in dendritic cell metabolism and function during *chlamydia* infection
Qing He, Morehouse School of Medicine, USA
Title: The use of new adjuvants and VLPs for the development of vaccines for emerging and infectious diseases
Gustavo Cabral de Miranda, University of Oxford, UK
Title: Pulmonary delivery of a mucosal nanocarrier vaccine for Pneumonia
Imran Saleem, Liverpool John Moores University, UK

Group Photo

Lunch Break

Session Chair: Francis Eko, Morehouse School of Medicine, USA
Session Co-chair: Talin Barissani-Asenbauer, Medical University of Vienna, Austria

Session Introduction

Title: Next-generation millisecond manufacture of genetic vaccines and lipid/polymer-based vaccines
Nadia Tagnaouti, Precision NanoSystems Inc., Canada
Title: A reasonable hope to cure HIV with the Tat Oyi vaccine: Results and follow up of a double blinded randomized phase I/IIa clinical trial in France
Erwann Loret, Aix Marseille University, France
Title: Evaluation of nanoparticle-delivered inactivated whole antigen against *Chlamydia psittaci* infection in SPF chickens
Cheng He, China Agricultural University, China
Title: Mucosal Immunization via conjunctiva: Where do we stand?
Talin Barissani-Asenbauer, Medical University of Vienna, Austria
Title: Use of corpuscular adjuvants for ocular mucosal immunization as a strategy for vaccine against trachoma
Aleksandra Inic-Kanada, Center of Ocular Inflammation and Infection, Austria

Coffee Break

Title: VVX001- a promising novel hepatitis B vaccine candidate
Rainer Henning, Viravaxx AG, Austria

Panel Discussion

End Of Day 1

Sylt 1-2

Keynote Forum

Introduction

Title: Conjugate rPA-PGA anthrax vaccine induces protective antibodies

Lallan Giri, Biologic Resources LLC, USA

Title: Development of vaccines using genetically engineered *Inoviruses*

Leondios G Kostrikis, University of Cyprus, Cyprus

Coffee Break

Sessions:

Biodefense Vaccine against Bioterrorism | Vaccines for Immune Mediated Diseases | Vaccines for Pregnant Women and Neonates | Antibodies : Engineering and Therapeutics | Animal Models and Clinical Trials

Session Chair: Leondios G Kostrikis, University of Cyprus, Cyprus
Session Co-Chair: Lallan Giri, Biologic Resources LLC, USA

Session Introduction

Title: Protection against bioterrorism
Lallan Giri, Biologics Resources LLC, USA
Title: When funding for medical countermeasures against rare, but detrimental agents is cost-effective
Mark Lawrence Johnson, MJ Lawrence Consulting, Germany
Title: An mRNA-based vaccine technology for next generation prophylactic vaccines
Susanne Rauch, CureVac, Germany
Title: ATMP Cell Therapy: Triumphs and constraints for unmet clinical needs
Shreemanta K Parida, Justus-Liebig University, Germany

Lunch Break & Poster Session

Title: Efficient expression of porcine circovirus type 2 virus-like particles in *Escherichia coli*
Guanggang Qu, Shandong Binzhou Animal Science and Veterinary Medicine Academy, China
Title: Comparison of susceptibility to measles in preterm infants versus term infants
Joseph L Mathew, Postgraduate Institute of Medical Education and Research, India
Title: Vaccines for key unmet Medical (Infectious Disease) needs in the developing world: Learning and reflections from the India Polio eradication success story
Aamir Shaikh, Assansa, India
Title: *Pneumococcal meningoencefalitis* in 50-day-old baby ended with lethal outcome: A case report
Liliya Pekova, University hospital (Stara Zagora), Bulgaria
Title: Promising results in the assessment of new vaccine candidates against *campylobacter* in poultry
Marine Meunier, French Agency for Food, Environmental and Occupational Health & Safety, France

Coffee Break

Panel Discussions

End Of Day 2

Closing Ceremony

conferenceseries.com

Scientific Program

10th Euro Global Summit and Expo on

Vaccines & Vaccination

June 16-18, 2016 Rome, Italy



UK: Conference Series llc LTD
47 Churchfield Road, London, W3 6AY

07:30-08:45 Registrations

Appia

conferenceseries.com 08:45-09:00

Opening Ceremony

Keynote Forum

09:00-09:05 Introduction

09:05-09:35 Title: Development of the full length single chain gp120-CD4 (FLSC), a novel vaccine for HIV prevention
Timothy R Fouts, Profectus Biosciences Inc., USA

09:35-10:05 Title: Vaccines moving beyond the next frontier
Rene Labatut, Sanofi Pasteur, France

Networking & Refreshments Break 10:05-10:25 @ Foyer area

10:25-10:55 Title: VGX-3100 drives regression of HPV16/18 CIN2/3 and robust cellular immune responses in blood and cervical tissue in a blinded, randomized, placebo-controlled phase 2b study
Prakash Bhuyan, Inovio Pharmaceuticals, USA

Group Photo

Track 1: Cancer Vaccines
Track 2: Vaccine Products and Delivery Technologies
Track 3: Vaccine Research and Development
Track 4: Vaccines for Respiratory Infections
Track 5: HIV Vaccines
Track 6: Veterinary vaccines

Session Chair: **Timothy R Fouts,** Profectus Biosciences Inc., USA
Session Co-chair: **Qingsheng Li,** University of Nebraska-Lincoln, USA

Session Introduction

10:55-11:15 Title: Pre-clinical evaluation of the therapeutic application of a vaccine targeting the 12 protease cleavage sites
Ma Luo, University of Manitoba, Canada

11:15:11:35 Title: Distinct transcriptome profiles of Gag-specific CD8+ T cells temporally correlated with the protection elicited by live attenuated SIV
Qingsheng Li, University of Nebraska-Lincoln, USA

11:35-11:55 Title: TAT, the forgotten target that could help to cure from HIV
Erwann P Loret, ETRAV Laboratory, France

11:55-12:15 Title: Community engagement during the Ebola vaccine trial in Guinea
Godwin Enwere, World Health Organization, Switzerland

12:15-12:35 Title: Pre-clinical toxicology considerations in vaccine
Nabil Al-Humadi, Food and Drug Administration, USA

Lunch Break 12:35-13:25 @ Restaurant

13:25-13:45 Title: Codon harmonization, a step beyond optimization to capture the natural rhythm of protein translation
Bettina Werle, Bioaster, France

13:45-14:05 Title: Development of lipid based oral vaccine formulations
Sarah Margaret Hook, University of Otago, New Zealand

14:05-14:25 Title: Viral vectored genetic vaccines: Current status and future perspectives
Antonella Folgori, Reithera SRL, Italy

14:25-14:45 Title: Active immunization against proprotein convertase subtilisin/kexin type 9 (PCSK9): A new strategy to control hyperlipidemia
Gunther Staffler, AFFiRiS AG, Austria

14:45-15:05 Title: Development of a production and purification platform for virus like particles (VLP) vaccine candidates: A case study
Anissa Boumlic-Courtade, Merck Life Science, France

15:05-15:25 Title: MATS: Global coverage estimates for 4CMenB, a novel multi-component meningococcal B vaccine
Duccio Medini, GSK Vaccines, Italy

Networking & Refreshments Break 15:25-15:45 @ Foyer area

15:45-16:05 Title: Implementing a randomized control trial (RCT) in the context of an Ebola epidemic
Godwin Enwere, World Health Organization, Switzerland

16:05-16:25 Title: Vaccination with self-adjuvanted protein nanoparticles provides protection against lethal influenza challenge
Peter Burkhard, Alpha-O Peptides AG, Switzerland

16:25-16:45 **Title: Plant expression platforms for vaccine production**
Kathleen Hefferon, Cornell University, USA

16:45-17:05 **Title: What do Lebanese women know about cervical cancer and human papillomavirus prevention? A report on awareness levels in urban communities**
Jacques Choucair, Saint Joseph University, Lebanon

Young Researchers Forum

17:05-17:20 **Title: Isolation and characteristics identification of bovine rotaviruses from vaccinated dairy calves in Morocco**
Ennima Imane , University Mohammed V of Rabat, Morocco

17:20-17:35 **Title: Bluetongue virus (BTV) serological survey and evidence of emergent BTV-8 serotype in Morocco**
Kamar Drif, Institut Agronomique et Veterinaire Hassan II, Morocco

17:35-17:50 **Title: Evaluation of the protection conferred by an attenuated vaccine (Mass-type H120) of avian infectious bronchitis against a new emerging Italy 02 genotype in Moroccan broiler chickens**
Khadija Khataby, University Hassan II of Casablanca, Morocco

Panel Discussion

Day 2 June 17, 2016

Appia

Keynote Forum

09:00-09:30 **Title: Towards affordable conjugate vaccines: Efficient chemistry and low cost carrier protein**
Andrew Lees, Fina Biosolutions LLC, USA

09:30-10:00 **Title: Human vaccines and vaccination for non-infectious diseases**
Giulio Filippo Tarro, Foundation T. & L. de Beaumont Bonelli for Cancer Research, Italy

Networking & Refreshments Break 10:00-10:20 @ Foyer area

10:20-10:50 **Title: Challenges and dilemmas about vaccines against the herpesviruses : The case of EBV**
Emmanuel Drouet, Université Grenoble-Alpes, France

Track 7: Vaccines against Infectious diseases
Track 8: Viral Vaccines
Track 9: Bacterial Vaccines
Track 10: Childhood Vaccines
Track 11: Hepatitis Vaccines
Track 12: Toxoid Vaccines

Session Chairs: Giulio Filippo Tarro, Foundation T. & L. de Beaumont Bonelli for Cancer Research, Italy
Andrew Lees, Fina Biosolutions LLC, USA

Session Introduction

10:50-11:10 **Title: Rapid development of an oral Zika virus vaccine**
Sean N Tucker, Vaxart Inc., USA

11:10-11:30 **Title: Preclinical development of HeV-sG as a vaccine and m102.4 as a post exposure prophylaxis against henipavirus infections**
Timothy R Fouts, Profectus Bio-Sciences, USA

11:30-11:50 **Title: Measles: Need for continued vaccination and novel vaccines post virus eradication**
S Louise Cosby, Agri-Food and Biosciences Institute, UK

11:50-12:10 **Title: Evaluation of genetic stability of transgenes in vaccine**
Ali Azizi, Sanofi Pasteur, Canada

12:10-12:30 **Title: Process development for pneumococcal protein vaccines based on recombinant pneumococcal surface protein A (PspA) and hybrids of PspA and pneumolysin toxoid**
Viviane Maimoni Goncalves, Instituto Butantan, Brazil

Lunch Break 12:30-13:20 @ Restaurant

13:20-13:40 **Title: The key person influences flu vaccination among health workers: Perspective study of social network**
Xiaoning Hao, China National Health Development Research Center, China

13:40-14:00 **Title: Pneumococcal conjugate vaccine: Use of pneumococcal surface protein A (PspA) as carrier**
Giovana Cappio Barazzone, Instituto Butantan, Brazil

14:00-14:20 **Title: Construction and immunological study on recombinant multi-epitope adenovirus vaccine for influenza virus**
Hui-jun Lu, Changchun Veterinary Institute of CAAS, China

14:20-14:40 **Title: Pneumococcal inactivated whole cell vaccine: Development of the production process**
Viviane Maimoni Goncalves, Instituto Butantan, Brazil

14:40-15:00 **Title: Knowledge, attitude and practices and influencing factors related to seasonal influenza vaccination among healthcare workers in Qingdao, China, 2013-14: A prospective cohort study**
Xiaoning Hao, China National Health Development Research Center, China

15:00-15:20 **Title: Polio outbreak review in the Middle East and polio immunization mop-up campaigns in the Lebanese/ Syrian refugees' context and post campaign results**
Randa Hamadeh, Ministry of Public Health, Lebanon

Networking & Refreshments Break 15:20-15:40 @ Foyer area

15:40-16:00 **Title: Prevalence of tuberculin negativity after BCG vaccination in the under five Saudi children and the need for revaccination**
Fahad Saleh Al-Tayyeb, King Abdulaziz Medical City, KSA

16:00-16:20 **Title: Vaccination of hepatitis B in healthy adults: Effect of sex and age, two protocols of revaccination in non-responders**
Jacques Choucair, Saint Joseph University, Lebanon

Panel Discussion

Breakout

Cassia Meeting Room

Workshop on
Revisiting HIV inactivation, elite controllers, immunogenetics and HIV therapeutic vaccines

Session Chairs: **Barbara Ensoli,** National AIDS Center-Istituto Superiore di Sanità, Ital
Felipe Garcia Alcaide, Hospital Clinic de Barcelona, Spain

09:00-09:30 **Title: Expanding the findings of RV144 to South Africa: P5 initiative**
Glenda Gray, South African Medical Research Council, South Africa

09:30-10:00 **Title: Therapeutic vaccination with Tat restores immune homeostasis, promotes proviral DNA decay and induces cross-clade neutralizing antibodies in patients on HAART: Results from phase II clinical trials in Italy and South Africa**
Barbara Ensoli, National AIDS Center-Istituto Superiore di Sanità, Italy

Networking & Refreshments Break 10:00-10:20 @ Foyer area

10:20-10:50 **Title: Current strategies for HIV remission: The role of therapeutic vaccines**
Felipe Garcia Alcaide, Hospital Clinic de Barcelona, Spain

10:50-11:20 **Title: Synthetic DNA vaccines for difficult mucosal viruses including HIV**
Jean D. Boyer, Inovio Pharmaceuticals Inc., USA

11:20-11:50 **Title: Potential development of inactivated HIV-1 transmitted/founder virus (T/F) vaccine**
Adan Rios, PhotoImmune Biotechnology Inc., USA

11:50-12:20 Discussion

Lunch Break 12:20-13:20 @ Restaurant

Session Chairs: **Marc H.V. Van Regenmortel,** Biotechnology School of the University of Strasbourg, France
Eric Sandstrom, Karolinska Institutet, Sweden

13:20-13:50 **Title: HIV vaccine development: Is a moral wrong occurring?**
Mike King, University of Otago, New Zealand

13:50-14:20 **Title: Reverse HIV vaccinology failed because it has no sound theoretical basis in the case of this virus**
Marc H.V. Van Regenmortel, Biotechnology School of the University of Strasbourg, France

14:20-14:50 **Title: HIV replication is suppressed by CD8+T- regulatory cells in elite controllers**
Jean Marie Andrieu, Paris-Descartes University, France

14:50-15:20 **Title: Concerns in the planning of therapeutic immunizations in HIV infected patients aiming to harness HLA E restricted CD8+T-cell HIV suppressive activity**
Eric Sandstrom, Karolinska Institutet, Sweden

Networking & Refreshments Break 15:20-15:40 @ Foyer area

15:40-16:10 **Title: Multiple immunogenetic aspects in susceptibility to HIV-1 infection progression toward AIDS and rational vaccine design**
Massimo Amicosante, University of Rome, Italy

Workshop Discussion

Poster Presentations 16:10-17:00

EVACC 01 **Role of insulin like growth factor-1 derived from macrophages in an influenza vaccine induced humoral immune response**
Jae-Hwan Nam, Catholic University of Korea, South Korea

EVACC 02 **Visualization of immune response to hepatitis B vaccination by in vivo small animal imaging**
Hyewon Youn, Seoul National University, South Korea

EVACC 03 **Development immunogen for protection against PRRSV infection using Korean isolates ORF5 protein expression using baculovirus expression system**
Sun Shin Yi, Soonchunhyang University, South Korea

EVACC 04 **Vaccine potentials of excretory-secretory antigens of 4 week old juveniles against *Fasciola gigantica* in mice**
Narin Changklungmoa, Burapha University, Thailand

EVACC 05 **Vaccine potentials of recombinant mature cathepsin L1H against *Fasciola gigantica* in mice**
Pornanan Kueakhai, Burapha University, Thailand

EVACC 06 **Characterization and vaccination of the cytosolic *Fasciola gigantica* superoxide dismutase**
Wipaphorn Jaikua, Mahidol University, Thailand

EVACC 07 **Study for manufacture and establishment of 1st national standard material for cell derived Japanese encephalitis vaccine (Beijing strain)**
Ji Young Hong, National Institute of Food and Drug Safety Evaluation, Korea

EVACC 08 **Histone deacetylase 10 (HDAC 10) deacetylates Foxp3 and modulates its stability**
Suna Gu, Chonbuk National University, Republic of Korea

EVACC 09 **In silico design of epitope based peptide vaccine against virulent strains of HN-Newcastle disease virus (NDV) in poultry species**
Marwa Mohamed Osman, Africa City of Technology, Sudan

Day 3 June 18, 2016

Appia

Track 13: DNA Vaccines
Track 14: Vaccine Safety and Efficacy
Track 15: Vaccine Adjuvants
Track 16: Tuberculosis Vaccines
Track 17: Vaccination for Pregnant Women
Track 18: Human Preventive and Therapeutic Vaccines

Session Chair: Emmanuel Drouet, Université Grenoble-Alpes, France
Session Co-Chair: Sheikh Mohammad Fazle Akbar, Toshiba General Hospital, Japan

Session Introduction

10:00-10:20 **Title: Vaccines for pregnant women - challenges and opportunities for harmonized safety monitoring**
Sonali Kochhar, Global Healthcare Consulting, India

10:20-10:40 **Title: Exploiting a high dose murine challenge model for HSV to identify potential DNA prime subunit boost vaccine strategies that could be translated to human clinical trials**
Timothy R Fouts, Profectus Biosciences Inc., USA

Networking & Refreshments Break 10:40-11:00 @ Foyer area

11:00-11:20 **Title: Operational experience and lessons learned on influenza vaccination post authorization safety studies**
Ombretta Palucci, Quintiles, Switzerland

11:20-11:40 **Title: Post-marketing surveillance of BCG vaccination**
Ruwen Jou, Tuberculosis Research Center at Centers for Disease Control, Taiwan

11:40-12:00 **Title: Novel vaccine adjuvants for animal infectious diseases**
Jishu Shi, Kansas State University, USA

12:00-12:20 **Title: Emerging market challenges: Development of a thermostable and immunologically active solid HPV vaccine formulation**
Ramesh Chintala, Merck & Co. Inc., USA

Lunch Break 12:20-13:10 @ Restaurant

13:10-13:30 **Title: Immunogenicity of VLP forming baculoviral DNA vaccine**
Young Bong Kim, Konkuk University, Republic of Korea

13:30-13:50 **Title: Targeting TLR9 and TLR21 to develop vaccine adjuvant for different species**
Tsung-Hsien Chuang, National Health Research Institutes, Taiwan

13:50-14:10 **Title: Therapeutic vaccines for treatment of allergic and autoimmune diseases**
Zhikang Peng, University of Manitoba, Canada

14:10-14:30 **Title: Therapeutic vaccines against chronic hepatitis-B virus and related complications**
Sheikh Mohammad Fazle Akbar, Toshiba General Hospital, Japan

Panel Discussion & Closing Ceremony

Bookmark your dates

18th International Conference on

Vaccine Adjuvatns Delivery Technologies

July 27-28, 2017 Chicago, USA

e-mail: mailto:vaccinedelivery@vaccineconference.com" vaccinedelivery@vaccineconference.com

Website: http://vaccinedelivery.conferenceseries.com/

UK: Conference Series llc LTD
47 Churchfield Road, London, W3 6AY

OMICS International
6th Floor, North Block, Divyasree Building, Raidurg Hyderabad, Telangana, INDIA-500032
Tel: +91-40-33432300
asia.pacific@conferenceseries.com

Toll free
Canada: +1-800-216-6499
Australia: +1-800-651-097
Europe: 0805-080048